Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials
Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...
NYSE: NVO
NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery
US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo...
Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...
Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...
Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...
Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...
Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...
Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China
In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...
Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA
China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...
Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities
Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference
Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...